ECSP045470A - Productos biologicos - Google Patents

Productos biologicos

Info

Publication number
ECSP045470A
ECSP045470A EC2004005470A ECSP045470A ECSP045470A EC SP045470 A ECSP045470 A EC SP045470A EC 2004005470 A EC2004005470 A EC 2004005470A EC SP045470 A ECSP045470 A EC SP045470A EC SP045470 A ECSP045470 A EC SP045470A
Authority
EC
Ecuador
Prior art keywords
biological products
antibody molecule
relates
present
specificity
Prior art date
Application number
EC2004005470A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9935990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045470(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045470A publication Critical patent/ECSP045470A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con una molécula de anticuerpo que tiene especificad para determinantes antigénicos del antígeno de linfocito CD22. La presente invención también se relaciona con los usos terapéuticos de la molécula de anticuerpo y los métodos para producir la molécula de anticuerpo.
EC2004005470A 2002-05-02 2004-12-02 Productos biologicos ECSP045470A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0210121.0A GB0210121D0 (en) 2002-05-02 2002-05-02 Biological products

Publications (1)

Publication Number Publication Date
ECSP045470A true ECSP045470A (es) 2005-01-28

Family

ID=9935990

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005470A ECSP045470A (es) 2002-05-02 2004-12-02 Productos biologicos

Country Status (34)

Country Link
US (8) US7355011B2 (es)
EP (1) EP1504035B9 (es)
JP (3) JP4486494B2 (es)
KR (3) KR101156796B1 (es)
CN (3) CN100384878C (es)
AT (1) ATE462729T3 (es)
AU (1) AU2003223007C1 (es)
BE (1) BE2017C068I2 (es)
CA (1) CA2484420C (es)
CO (1) CO5631451A2 (es)
CY (3) CY1110134T1 (es)
DE (1) DE60331910D1 (es)
DK (1) DK1504035T6 (es)
EC (1) ECSP045470A (es)
ES (1) ES2341708T7 (es)
FR (1) FR17C1062I2 (es)
GB (1) GB0210121D0 (es)
HU (2) HUS1700056I1 (es)
IL (1) IL164923A (es)
LT (2) LTPA2017043I1 (es)
LU (2) LUC00058I2 (es)
MX (1) MXPA04010787A (es)
NL (1) NL300920I2 (es)
NO (3) NO336201B1 (es)
NZ (1) NZ536757A (es)
PL (1) PL218433B1 (es)
PT (1) PT1504035E (es)
RU (1) RU2342401C2 (es)
SG (1) SG161744A1 (es)
SI (1) SI1504035T1 (es)
TW (1) TWI324161B (es)
UA (1) UA92580C2 (es)
WO (1) WO2003093320A2 (es)
ZA (1) ZA200408851B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1448584B1 (en) * 2001-09-26 2010-05-19 The Government of the United States of America as represented by The Secretary of Health and Human Services Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
EP1485130A4 (en) 2002-02-21 2006-11-22 Univ Duke REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT2371392E (pt) * 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AR052774A1 (es) * 2004-10-08 2007-04-04 Wyeth Corp Inmunoterapia para trastornos autoinmunes
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP2650306A1 (en) * 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1998799B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
HRP20140172T1 (hr) * 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
CN103415621A (zh) 2011-01-14 2013-11-27 雷德伍德生物科技股份有限公司 醛标记免疫球蛋白多肽及其使用方法
CA2827859A1 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists
MX361533B (es) * 2012-04-26 2018-12-07 Bioatla Llc Anticuerpos anti-cd22.
EP3838921A3 (en) 2012-07-03 2021-09-01 Washington University Antibodies to tau
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
ES2718903T3 (es) 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
CN103214578B (zh) * 2013-05-10 2014-05-28 北京东方百泰生物科技有限公司 一种新型的人源化抗cd22抗体
PE20161413A1 (es) 2013-11-04 2017-01-10 Stemcentrx Inc Conjugados de anticuerpo anti-efna4-farmaco
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
HRP20220893T1 (hr) * 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
GB201601077D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
US20180110856A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
CN112888709B (zh) * 2018-03-30 2024-10-29 优瑞科生物技术公司 标靶cd22的构建体和其用途
US12448453B2 (en) * 2020-04-02 2025-10-21 Nanjing IASO Biotechnology Co., Ltd. Fully human anti-human CD22 chimeric antigen receptor and application thereof
US20230331840A1 (en) * 2020-08-27 2023-10-19 Fapon Biotherapy Inc. Cd22 antibody and application thereof
WO2022262783A1 (zh) * 2021-06-16 2022-12-22 西安宇繁生物科技有限责任公司 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用
CA3230370A1 (en) * 2021-08-27 2023-03-02 Peptron, Inc. Novel anti-muc1 antibody and use thereof
CN116217727B (zh) * 2021-12-06 2025-04-29 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957362A (en) * 1972-10-02 1976-05-18 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK1013666T3 (da) * 1990-06-27 2006-08-14 Univ Princeton Proteinkompleks p53/p90
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5714340A (en) * 1992-12-22 1998-02-03 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassay elements having a receptor zone
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
AU703152B2 (en) 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE201445T1 (de) 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
WO1996004925A1 (en) * 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5714586A (en) * 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) * 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20020141990A1 (en) * 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
JP2001510329A (ja) * 1996-11-01 2001-07-31 スミスクライン・ビーチャム・コーポレイション ヒトモノクローナル抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998041641A1 (en) 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3919235B2 (ja) 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
DE50001665D1 (de) * 1999-10-12 2003-05-08 Connex Ges Zur Optimierung Von Verbessertes verfahren zum nachweis von säure-resistenten bakterien der gattung helicobacter im stuhl
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU6461201A (en) * 2000-07-12 2002-01-21 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
PT2371392E (pt) 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP2650306A1 (en) * 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
AU2003223007C1 (en) 2019-08-08
CA2484420A1 (en) 2003-11-13
FR17C1062I1 (es) 2018-02-16
US20030235869A1 (en) 2003-12-25
TW200307690A (en) 2003-12-16
NZ536757A (en) 2006-06-30
LTPA2017043I1 (lt) 2018-01-10
NO2017068I1 (no) 2017-12-21
CY2017046I1 (el) 2018-12-12
GB0210121D0 (en) 2002-06-12
CY2017045I2 (el) 2019-11-27
NL300920I2 (nl) 2021-04-15
MXPA04010787A (es) 2005-03-07
NO20044742L (no) 2004-12-22
JP2010022372A (ja) 2010-02-04
CY2017045I1 (el) 2019-11-27
CY2017046I2 (el) 2018-12-12
US20160326247A1 (en) 2016-11-10
US20210371547A1 (en) 2021-12-02
NO2017069I1 (no) 2017-12-21
US7355011B2 (en) 2008-04-08
US7919606B2 (en) 2011-04-05
CN101134779A (zh) 2008-03-05
EP1504035B1 (en) 2010-03-31
LTPA2017044I1 (lt) 2018-01-10
LUC00058I1 (es) 2017-12-27
HK1071762A1 (en) 2005-07-29
JP2006506955A (ja) 2006-03-02
LUC00057I1 (es) 2017-12-27
WO2003093320A2 (en) 2003-11-13
CN1662558A (zh) 2005-08-31
PL218433B1 (pl) 2014-12-31
EP1504035B3 (en) 2017-12-20
CN101134779B (zh) 2013-03-13
PL373277A1 (en) 2005-08-22
CA2484420C (en) 2014-09-16
ES2341708T7 (es) 2018-04-11
FR17C1062I2 (fr) 2020-05-29
LUC00057I2 (es) 2018-02-26
KR101386376B1 (ko) 2014-04-16
HUS1700056I1 (hu) 2018-07-30
US20170145114A1 (en) 2017-05-25
EP1504035B9 (en) 2018-10-17
US20070059307A1 (en) 2007-03-15
US20110165659A1 (en) 2011-07-07
KR101156796B1 (ko) 2012-06-21
JP2013230158A (ja) 2013-11-14
DK1504035T3 (da) 2010-06-07
SG161744A1 (en) 2010-06-29
ZA200408851B (en) 2006-01-25
DE60331910D1 (de) 2010-05-12
BE2017C068I2 (es) 2022-08-09
SI1504035T1 (sl) 2010-07-30
EP1504035A2 (en) 2005-02-09
CN103172742A (zh) 2013-06-26
KR20120127513A (ko) 2012-11-21
NO336201B3 (no) 2015-06-15
CO5631451A2 (es) 2006-04-28
JP5377173B2 (ja) 2013-12-25
WO2003093320A3 (en) 2004-02-05
KR20110004463A (ko) 2011-01-13
TWI324161B (en) 2010-05-01
RU2004135103A (ru) 2005-10-27
LUC00058I2 (es) 2018-02-26
DK1504035T6 (en) 2018-03-12
ATE462729T3 (de) 2010-04-15
AU2003223007A1 (en) 2003-11-17
LTC1504035I2 (lt) 2022-04-11
AU2003223007B2 (en) 2009-07-16
RU2342401C2 (ru) 2008-12-27
IL164923A0 (en) 2005-12-18
KR101238970B1 (ko) 2013-03-04
EP1504035B8 (en) 2018-02-28
JP4486494B2 (ja) 2010-06-23
US20120302739A1 (en) 2012-11-29
NO336201B1 (no) 2015-06-15
ES2341708T3 (es) 2010-06-25
UA92580C2 (ru) 2010-11-25
JP5920934B2 (ja) 2016-05-18
KR20050025167A (ko) 2005-03-11
PT1504035E (pt) 2010-06-07
HK1186479A1 (zh) 2014-03-14
US20100021995A1 (en) 2010-01-28
US8895714B2 (en) 2014-11-25
CN103172742B (zh) 2016-05-11
HUS1700055I1 (hu) 2018-07-30
CY1110134T1 (el) 2015-01-14
IL164923A (en) 2012-03-29
CN100384878C (zh) 2008-04-30
NL300920I1 (es) 2018-01-03

Similar Documents

Publication Publication Date Title
ECSP045470A (es) Productos biologicos
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
ECSP088613A (es) Moléculas de anticuerpo que tienen especificidad para la il-6 humana
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
AR091703A1 (es) Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
SI1557462T1 (sl) Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
ECSP066379A (es) Anticuerpos rg1 y usos de los mismos
EA200800812A1 (ru) Композиции антитела против cd3
PE20150643A1 (es) Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
AR071104A1 (es) Metodo para determinar una proteina de haemophilus parasuis que comprende un determinante antigenico de reaccion cruzada
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
AR027738A1 (es) Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
ECSP045099A (es) Productos biologicos
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6
ECSP034474A (es) Nuevo tratamiento
AR064925A2 (es) Proceso para la purificacion de una proteina mage para preparar una vacuna, dicha vacuna y su uso para la fabricacion de un medicamento